title: Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group.
abstract: Although fungal urinary tract infections are an increasing nosocomial problem, the significance of funguria is still not clear. This multicenter prospective surveillance study of 861 patients was undertaken to define the epidemiology, management, and outcomes of funguria. Diabetes mellitus was present in 39% of patients, urinary tract abnormalities in 37.7%, and malignancy in 22.2%; only 10.9% had no underlying illnesses. Concomitant nonfungal infections were present in 85%, 90% had received antimicrobial agents, and 83.2% had urinary tract drainage devices. Candida albicans was found in 51.8% of patients and Candida glabrata in 15.6%. Microbiological and clinical outcomes were documented for 530 (61.6%) of the 861 patients. No specific therapy for funguria was given to 155 patients, and the yeast cleared from the urine of 117 (75.5%) of them. Of the 116 patients who had a catheter removed as the only treatment, the funguria cleared in 41 (35.3%). Antifungal therapy was given to 259 patients, eradicating funguria in 130 (50.2%). The rate of eradication with fluconazole was 45.5%, and with amphotericin B bladder irrigation it was 54.4%. Only 7 patients (1.3%) had documented candidemia. The mortality rate was 19.8%, reflecting the multiple serious underlying illnesses found in these patients with funguria.
authors.affiliation: University of Michigan and Veterans Affairs Medical Center, Ann Arbor, MI 48105, USA. ckauff@umich.edu
authors.forename: C A
authors.initials: CA
authors.lastname: Kauffman
authors.forename: J A
authors.initials: JA
authors.lastname: Vazquez
authors.forename: J D
authors.initials: JD
authors.lastname: Sobel
authors.forename: H A
authors.initials: HA
authors.lastname: Gallis
authors.forename: D S
authors.initials: DS
authors.lastname: McKinsey
authors.forename: A W
authors.initials: AW
authors.lastname: Karchmer
authors.forename: A M
authors.initials: AM
authors.lastname: Sugar
authors.forename: P K
authors.initials: PK
authors.lastname: Sharkey
authors.forename: G J
authors.initials: GJ
authors.lastname: Wise
authors.forename: R
authors.initials: R
authors.lastname: Mangi
authors.forename: A
authors.initials: A
authors.lastname: Mosher
authors.forename: J Y
authors.initials: JY
authors.lastname: Lee
authors.forename: W E
authors.initials: WE
authors.lastname: Dismukes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D002404:Catheterization; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D011159:Population Surveillance; D011446:Prospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D014556:Urine / Q000382:microbiology
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole